<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03456362</url>
  </required_header>
  <id_info>
    <org_study_id>RF-2011-02349953</org_study_id>
    <nct_id>NCT03456362</nct_id>
  </id_info>
  <brief_title>Cerebellar rTMS to Improve Gait Recovery</brief_title>
  <official_title>Promoting Motor Recovery in Patients With Stroke by Enhancing Cerebellar-cortical Plasticity: a Randomized Double Blinded Controlled Repetitive TMS Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I.R.C.C.S. Fondazione Santa Lucia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I.R.C.C.S. Fondazione Santa Lucia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The cerebellum is known to be strongly implicated in the functional reorganization of motor
      networks in stroke patients, especially for gait an balance functions. Repetitive
      transcranial magnetic stimulation of the cerebellum can be used to enhance these adaptive
      processes in stroke recovery. In this randomized, double blind, sham-controlled trial we aim
      to investigate the efficacy and safety of cerebellar intermittent theta burst stimulation
      coupled with intensive physical therapy in promoting gait recovery in hemiparetic patients
      due to recent stroke in the territory of the contralateral middle cerebral artery
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2014</start_date>
  <completion_date type="Actual">October 1, 2017</completion_date>
  <primary_completion_date type="Actual">June 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Berg Balance Scale (BBS) for gait and balance</measure>
    <time_frame>Change from baseline at the end of three weeks treatment</time_frame>
    <description>Assessment of gait and balance functions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fugl-Meyer Assessment (FMA) scale</measure>
    <time_frame>Change from baseline at the end of three weeks treatment</time_frame>
    <description>Assessment of motor functions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index (BI)</measure>
    <time_frame>Change from baseline at the end of three weeks treatment</time_frame>
    <description>Assessment of functional abilities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurophysiological assessment of cortical activity</measure>
    <time_frame>Change from baseline at the end of three weeks treatment</time_frame>
    <description>evaluation of cortical activity by means of TMS in combination with EEG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait analysis</measure>
    <time_frame>Change from baseline at the end of three weeks treatment</time_frame>
    <description>evaluation of locomotion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Stroke</condition>
  <condition>Gait, Hemiplegic</condition>
  <arm_group>
    <arm_group_label>Cerebellar iTBS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intermittent theta burst stimulation applied immediately before the daily physical therapy session for a period of three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham iTBS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham intermittent theta burst stimulation applied immediately before the daily physical therapy session for a period of three weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION</intervention_name>
    <description>theta burst stimulation (TBS) is a novel form of repetitive transcranial magnetic stimulation that mimics protocols inducing long-term potentiation (LTP) or long-term depression (LTD) in animal models. Whereas continuous TBS (cTBS) induces long-lasting inhibition of cortical areas, iTBS exerts the opposite effect, increasing cerebellar excitability</description>
    <arm_group_label>Cerebellar iTBS</arm_group_label>
    <arm_group_label>Sham iTBS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First ever-chronic ischemic stroke, i.e. at least 6 months after the stroke event,

          -  Left or right subcortical or cortical lesion of the middle cerebral artery with
             medium-severity stroke NHISS &lt;15 (All lesions must be documented by magnetic resonance
             imaging (T1- and T2-weighted images; 1.5T, GE scanners)

          -  No contraindication to brain MRI

          -  MEP recordable in order to evaluate the resting motor threshold (RMT)

        Exclusion Criteria:

          -  Epilepsy

          -  Severe general impairment or concomitant diseases (tumors, etc.)

          -  Age&gt; 80 years

          -  Infections in progress

          -  Patients with neurological diseases beyond stroke or with neuropsychiatric disorders
             or with neuropsychological disorders that could potentially compromise informed
             consent or compliance during the study.

          -  Treatment with benzodiazepines, baclofen, antidepressants, clonidine, beta blockers
             and other potentially interfering drug treatments on plasticity phenomena.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Santa Lucia Foundation</name>
      <address>
        <city>Rome</city>
        <zip>00179</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2018</study_first_submitted>
  <study_first_submitted_qc>March 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>I.R.C.C.S. Fondazione Santa Lucia</investigator_affiliation>
    <investigator_full_name>Giacomo Koch</investigator_full_name>
    <investigator_title>Head of Laboratory</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Gait Disorders, Neurologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

